These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331 [TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538 [TBL] [Abstract][Full Text] [Related]
19. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961 [TBL] [Abstract][Full Text] [Related]
20. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]